91 A recent systematic review and meta-analysis has shed light on the treatment of skull base chondrosarcoma, a rare and locally invasive form of bone cancer. The findings, published in Frontiers in Oncology, reveal that while particle beam therapy (PT) and conventional radiotherapy are effective in controlling tumour growth and improving survival rates, the risk of adverse effects, such as temporal lobe necrosis, remains a significant concern. Skull base chondrosarcoma is a cancerous tumour that grows in the cells of the skull base that make cartilage. It is very hard to treat because it is in a hard-to-reach place. Surgical resection, though the primary treatment method, is often insufficient due to the difficulty in achieving complete tumour removal. As a result, postoperative radiotherapy is widely recommended to manage residual tumour cells and prevent recurrence. The review looked at 21 studies that were published between 1990 and 2022 and compared the effectiveness of proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) to other photon-based radiotherapy methods, such as three-dimensional conformal radiotherapy (3DCRT). PT is known for its precision, targeting tumours with high doses of radiation while minimising damage to surrounding healthy tissues. This is especially advantageous in treating skull base chondrosarcoma, where the proximity to critical structures like the brain increases the risk of complications. The study found that after undergoing PT, patients exhibited excellent survival rates. The overall survival rate at three years was 94.1%, and at five years, it was 93.9%. In terms of tumour control, the local control rates were equally impressive, with 95.4% at three years and 90.1% at five years. These outcomes were significantly better than those reported for 3DCRT, where survival rates ranged between 71% and 82%. However, the benefits of PT are not without risks. One of the most concerning adverse effects observed in the studies was temporal lobe necrosis, a serious condition that can arise from high doses of radiation. The incidence of this complication varied widely, with rates ranging from 1% to 18%, and a median incidence of 7%. Temporal lobe necrosis can lead to cognitive impairment and other neurological issues, making it a critical factor for clinicians to consider when deciding on a treatment plan. Pituitary hypofunction, which affects the hormonal balance that the pituitary gland controls, is one of the other negative effects of PT in addition to temporal lobe necrosis. The incidence of this condition was found to be between 9% and 27%, with a median of 16%, highlighting the need for careful monitoring of patients undergoing PT. Despite these risks, PT remains a promising option for patients with skull base chondrosarcoma, particularly when surgical resection is incomplete or impossible. Advances in radiotherapy techniques continue to improve outcomes, but further research is needed to refine treatment protocols and reduce the incidence of adverse effects. The study concludes that PT is a valuable treatment modality for skull base chondrosarcoma, offering high survival and tumour control rates.But the long-term risks associated with high-dose radiation, particularly in delicate areas like the skull base, underscore the need for ongoing innovation in radiotherapy technology to balance efficacy with safety. Individualised treatment plans that take into account the distinctive characteristics of each patient’s tumour and overall health will be crucial in improving outcomes and quality of life for those suffering from this uncommon and difficult cancer as clinicians weigh its potential benefits against its potential risks.